Bristol-Myers Squibb Co.: PharmaVitae Profile

Date: March 1, 2011
Pages: 84
Price:
US$ 5,700.00
Publisher: Datamonitor
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BC96C108490EN
Leaflet:

Download PDF Leaflet

Bristol-Myers Squibb Co.: PharmaVitae Profile
Introduction

This analysis examines the historical and forecast performance for Bristol-Myers Squibb in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits
  • Gain insight into Bristol-Myers Squibb's strategic outlook across the next 6 years
  • Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Strategic insight into the prospects for BMS over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered
  • Benchmark BMS's performance against key rivals in the prescription pharmaceutical sector
  • Determine the value of BMS's piepline and other strategies the company is taking to counteract an imminent wave of generic compeitition.
  • Assess what makes BMS a model biopharma company and why its newfound focus could lead to the industry's next megamerger.
Executive Summary
Key findings
Bristol-Myers Squibb prescription pharma sales outlook
Bristol-Myers Squibb financial outlook
Key developments
  [Missing title]
  Upcoming developments
SWOT analysis
  Strengths
  Weaknesses
  Opportunities
  Threats

ABOUT THIS PROFILE

PharmaVitae Explorer database
Chapter structure
  Strategic Insight
  Company Introduction
  Company Sales
  Company Financials
  Key Products
Data sourcing
  Analyst consensus

STRATEGIC INSIGHT

Key findings
Strategic insight
  BMS expiry decline fastest of Big Pharma

COMPANY INTRODUCTION

Key findings
Background
Key corporate developments
  Squibb
  Bristol-Myers Squibb
M&A strategy
  M&A history
  M&A strategy

SALES ANALYSIS

Key findings
Prescription pharmaceutical sales and growth rate analysis, 2004–16
Product analysis
  Product analysis, 2004–10
  Product analysis, 2010–16
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
  Launch analysis, 2010–16
  Core analysis, 2010–16
  Expiry analysis, 2010–16
  Launch/core/expiry configuration, 2010–16
Molecule type analysis
Externalization analysis

FINANCIAL ANALYSIS

Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2004-10
Operating costs and profit analysis
  Operating performance analysis, 2004–10
  Operating performance analysis, 2010–16

PRODUCT ANALYSIS

Overview
  Plavix
  Sprycel
  Orencia
  Reyataz
  Baraclude
  Onglyza
  Nulojix
  Sustiva
  Dapagliflozin
Bristol-Myers Squibb pipeline overview

APPENDIX

Abbreviations
Exchange rates

Ask Your Question

Bristol-Myers Squibb Co.: PharmaVitae Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: